Best of the Week
Most Popular
1. Investing in a Bubble Mania Stock Market Trending Towards Financial Crisis 2.0 CRASH! - 9th Sep 21
2.Tech Stocks Bubble Valuations 2000 vs 2021 - 25th Sep 21
3.Stock Market FOMO Going into Crash Season - 8th Oct 21
4.Stock Market FOMO Hits September Brick Wall - Evergrande China's Lehman's Moment - 22nd Sep 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
7.AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
8.Why Silver Price Could Crash by 20%! - 5th Oct 21
9.Powell: Inflation Might Not Be Transitory, After All - 3rd Oct 21
10.Global Stock Markets Topped 60 Days Before the US Stocks Peaked - 23rd Sep 21
Last 7 days
Ravencoin RVN About to EXPLODE to NEW HIGHS! Last Chance to Buy Before it goes to the MOON! - 21st Oct 21
Stock Market Animal Spirits Returning - 21st Oct 21
Inflation Advances, and So Does Gold — Except That It Doesn’t - 21st Oct 21
Why A.I. Is About To Trigger The Next Great Medical Breakthrough - 21st Oct 21
Gold Price Slowly Going Nowhere - 20th Oct 21
Shocking Numbers Show Government Crowding Out Real Economy - 20th Oct 21
Crude Oil Is in the Fast Lane, But Where Is It Going? - 20th Oct 21
3 Tech Stocks That Could Change The World - 20th Oct 21
Best AI Tech Stocks ETF and Investment Trusts - 19th Oct 21
Gold Mining Stocks: Will Investors Dump the Laggards? - 19th Oct 21
The Most Exciting Medical Breakthrough Of The Decade? - 19th Oct 21
Prices Rising as New Dangers Point to Hard Assets - 19th Oct 21
It’s not just Copper; GYX indicated cyclical the whole time - 19th Oct 21
Chinese Tech Stocks CCP Paranoia, VIES - Variable Interest Entities - 19th Oct 21
Inflation Peaked Again, Right? - 19th Oct 21
Gold Stocks Bouncing Hard - 19th Oct 21
Stock Market New Intermediate Bottom Forming? - 19th Oct 21
Beware, Gold Bulls — That’s the Beginning of the End - 18th Oct 21
Gold Price Flag Suggests A Big Rally May Start Soon - 18th Oct 21
Inflation Or Deflation – End Result Is Still Depression - 18th Oct 21
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector - 18th Oct 21
US Economy and Stock Market Addicted to Deficit Spending - 17th Oct 21
The Gold Price And Inflation - 17th Oct 21
Went Long the Crude Oil? Beware of the Headwinds Ahead… - 17th Oct 21
Watch These Next-gen Cloud Computing Stocks - 17th Oct 21
Overclockers UK Custom Built PC 1 YEAR Use Review Verdict - Does it Still Work? - 16th Oct 21
Altonville Mine Tours Maze at Alton Towers Scarefest 2021 - 16th Oct 21
How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
The Only way to Crush Inflation (not stocks) - 14th Oct 21
Why "Losses Are the Norm" in the Stock Market - 14th Oct 21
Sub Species Castle Maze at Alton Towers Scarefest 2021 - 14th Oct 21
Which Wallet is Best for Storing NFTs? - 14th Oct 21
Ailing UK Pound Has Global Effects - 14th Oct 21
How to Get 6 Years Life Out of Your Overclocked PC System, Optimum GPU, CPU and MB Performance - 13th Oct 21
The Demand Shock of 2022 - 12th Oct 21
4 Reasons Why NFTs Could Be The Future - 12th Oct 21
Crimex Silver: Murder Most Foul - 12th Oct 21
Bitcoin Rockets In Preparation For Liftoff To $100,000 - 12th Oct 21
INTEL Tech Stock to the MOON! INTC 2000 vs 2021 Market Bubble WARNING - 11th Oct 21
AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
Stock Market Wall of Worry Meets NFPs - 11th Oct 21
Stock Market Intermediate Correction Continues - 11th Oct 21
China / US Stock Markets Divergence - 10th Oct 21
Can US Save Taiwan From China? Taiwan Strait Naval Battle - PLA vs 7th Fleet War Game Simulation - 10th Oct 21
Gold Price Outlook: The Inflation Chasm Between Europe and the US - 10th Oct 21
US Real Estate ETFs React To Rising Housing Market Mortgage Interest Rates - 10th Oct 21
US China War over Taiwan Simulation 2021, Invasion Forecast - Who Will Win? - 9th Oct 21
When Will the Fed Taper? - 9th Oct 21
Dancing with Ghouls and Ghosts at Alton Towers Scarefest 2021 - 9th Oct 21
Stock Market FOMO Going into Crash Season - 8th Oct 21
Scan Computers - Custom Build PC 6 Months Later, Reliability, Issues, Quality of Tech Support Review - 8th Oct 21
Gold and Silver: Your Financial Main Battle Tanks - 8th Oct 21
How to handle the “Twin Crises” Evergrande and Debt Ceiling Threatening Stocks - 8th Oct 21
Why a Peak in US Home Prices May Be Approaching - 8th Oct 21
Alton Towers Scarefest is BACK! Post Pandemic Frights Begin, What it's Like to Enter Scarefest 2021 - 8th Oct 21
AJ Bell vs II Interactive Investor - Which Platform is Best for Buying US FAANG Stocks UK Investing - 7th Oct 21
Gold: Evergrande Investors' Savior - 7th Oct 21
Here's What Really Sets Interest Rates (Not Central Banks) - 7th Oct 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Are Biotechnology Stocks Heading for A Downturn?

Companies / Healthcare Sector Nov 04, 2009 - 02:35 AM GMT

By: Oakshire_Financial

Companies

Best Financial Markets Analysis ArticleScience always looks to the future, and there's not much science that's more exciting than biotechnology.

After all, this is the field with big promises for better and longer lives for all of us through applied biology in agriculture, food science, and medicine. But although the term 'biotechnology' is often refers to futuristic genetic engineering, the industry is far broader than genetics alone.


The promise is there. But the risks are too.

Biotech is quite risky since promising drugs or treatments can fail to get government approval and thus the associated large research & development budget is wasted. Companies can spend literally hundreds of millions of dollars devising products that they eventually can't even sell. And that's for the products that actually get that far – there are all kinds of failed research efforts that fizzle just after they get started.

But for the ones that make it, an approved drug, treatment, or piece of equipment is a gold mine.

Biotech Leaves the S&P In Its Dust

The main index used to track the major biotechnology companies is the Biotechnology Index (BTK), an equal dollar weighted index which measures the performance of 20 companies involved in recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics.

So how have these 20 companies been doing?

 

http://secure.campaigner.com/accountsmedia/6000/chow%2011-2-09%201.JPG

 

Pretty well when compared to the S&P 500 with a 30%+ gain even after a recent fall from 52 week highs.

It's clear that even if most other industries are mired in the doldrums of earnings (and expectations) mediocrity, people are still seeing promise in biotech.

But is the biotech boom over? Let's take a closer look...

http://secure.campaigner.com/accountsmedia/6000/chow%2011-2-09%202.JPG

 

In this daily chart of BTK, we see that the MACD and RSI indicators are dropping fast and are close to (or already in) the 'buy zone'.

However, it looks like there might be a bit more of a drop to come. That's based on two things we can see in this chart:

  1. We aren't yet seeing a reversal candlestick that would indicate a bottom is in, and
  2. There's no obvious support at this price level.

We could see some support at 835, however as the market previously turned around at that level.

So if we're going to start positioning ourselves for a future buy at some point, what's the best way to do it?


Biotech ETFs For Diversity's Sake

Due to the extreme risks of holding single biotech stocks (the drops and rises can be truly heart-stopping – especially if you're caught on the wrong side of them!) it's better to hedge your risk with a good ETF (Exchange Traded Fund) instead.

The following chart compares 6 different biotech ETFs against the BTK index itself...


http://secure.campaigner.com/accountsmedia/6000/chow%2011-2-09%203.JPG

As you can see, there's only one fund (First Trust Amex Biotechnology Trust, symbol FBT) that's doing as well as BTK itself. In fact, it's mirroring BTK which isn't much of a surprise when you learn that it was designed to do so.

The other funds are not performing nearly as well despite their very different strategies.

The iShares Nasdaq Biotechnology Trust (IBB – the pink line shown in the comparison chart) holds the largest number of stocks (approximately 120+) of any of the ETFs and it's also the most actively traded. You're up about 12% over the year with their strategy.

That's still better than HOLDRS Biotech ETF (BBH – the black line) which is very unevenly balanced due to its "grantor trust" status and holds few stocks. This cripples its trading strategy as it can't alter its underlying holdings except as a result of corporate actions.

But the SPDR S&P Biotech (XBI – the purple line) holds up the bottom of the chart. How this fund could lose money when BTK is performing so well is stunning. Theoretically this fund follows a similar strategy as top performer FBT but clearly the managers have not been on the ball at all.

The others are the middle of the pack, and it seems that FBT is the vehicle of choice for trading (or investing in) the biotechnology sector.


Broaden Your Horizons For Less Risk


Biotech is frequently considered a subset of the larger healthcare sector.

So if you still think biotech is too risky, you could look at healthcare too. After all, people are still getting sick and injured (and getting old) no matter what the economy does.

Here's the NYSE Healthcare Index (NYP), which is comprised of 108 different holdings as of this writing...

 

http://secure.campaigner.com/accountsmedia/6000/chow%2011-2-09%204.JPG

 

As you can see, this index is holding up even better than BTK, although it looks to also be ripe for a bit of a fall in the near future too.

If the bull trend remains intact, a logical buying point would be at the 50 day moving average.

So what's doing best in that sector?


http://secure.campaigner.com/accountsmedia/6000/chow%2011-2-09%205.JPG

Well, First Trust is again a clear winner with its FirstTrust AlphaDEX Healthcare fund (FXH). It's dramatically outperforming everything else in this comparison chart including the NYP index itself.

This ETF is designed to track the StrataQuant Health Care which employs the AlphaDEX stock selection methodology to select stocks from the Russell 1000 Index. This AlphaDEX strategy is based on a large number of fundamental factors, but whatever they're doing with that methodology, it's obviously working wonderfully well.

Meanwhile, the next closest contender is the Rydex S&P Equal Weight Health Care ETF (RYH) which seeks to replicate the performance of the S&P Equal Weight Index Health Care index (yet another lesser known but more impressive index than NYP).

So there you have it. The biotech (and healthcare) sectors look likely to drop a bit in the next few days or even weeks. But you now have some targeted 'buy' levels for the better-known benchmark indexes as well as the best performing ETF in each area.

Remember that science (and healthcare) is unlikely to take a backward step no matter how foolish the decisions coming from Washington. That makes these sectors relatively safe bets in an otherwise uncertain economy.

Good investing,

Nick Thomas
Analyst, Oxbury Research

Nick Thomas is a seasoned veteran of technical analysis and has mastered all intra-day trading in stocks, options, futures and forex. He prefers to scout investments as one asset class of many and shapes his investment strategies accordingly. He writes extensively about offshore banking and offshore tax havens and is active in the career development field of independent investment research.

Oxbury Research originally formed as an underground investment club, Oxbury Publishing is comprised of a wide variety of Wall Street professionals - from equity analysts to futures floor traders – all independent thinkers and all capital market veterans.

© 2009 Copyright Oxbury Research - All Rights Reserved
Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.

Oxbury Research Archive

© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in